Puma Biotechnology, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative cancer therapeutics. Its primary products include NERLYNX® (neratinib), a potent irreversible tyrosine kinase inhibitor for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, approved by the U.S. FDA and marketed in the United States since 2017. NERLYNX is also approved for combination treatment in advanced or metastatic HER2-positive breast cancer and authorized in the European Union and multiple international regions including Canada, Latin America, Greater China, Israel, Southeast Asia, Australia, New Zealand, South Korea, the Middle East, and parts of Africa. Puma also develops alisertib, an orally administered, selective inhibitor of aurora kinase A, targeting metastatic breast cancer and other cancers. The company in-licenses drug candidates and pursues clinical development to expand product indications. Founded in 2010 and headquartered in Los Angeles, California, Puma Biotechnology has recently reported an 8% increase in U.S. NERLYNX sales and ongoing clinical trials with interim data for alisertib expected in late 2025. It has expanded commercialization partnerships notably in Eastern Europe and Central Asia and secured financial backing through note purchase agreements to support its commercial and R&D activities. The company remains focused on enhancing cancer care by advancing its flagship product NERLYNX and expanding its oncology pipeline with alisertib and other in-licensed candidates.
Company News
Comparing TG Therapeutics (NASDAQ:TGTX) and Puma Biotechnology (NASDAQ:PBYI)
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
3,804,736 Shares in Puma Biotechnology, Inc. $PBYI Bought by BlackRock Inc.
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology Q2 Earnings Call Highlights
Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates
Puma Biotechnology Reports Second Quarter 2026 Financial Results
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Q1 Earnings Call Highlights
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised